HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Chenxiong Le Selected Research

sifalimumab

1/2014A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients.
11/2011Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.
3/2010A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Chenxiong Le Research Topics

Disease

2Respiratory Tract Infections (Respiratory Tract Infection)
01/2020 - 01/2019
1Pneumonia (Pneumonitis)
01/2019
1Clostridium Infections
01/2019
1Infections
01/2019
1Polymyositis
01/2014
1Dermatomyositis (Dermatopolymyositis)
01/2014
1Myositis (Idiopathic Inflammatory Myopathies)
01/2014
1Systemic Lupus Erythematosus (Libman-Sacks Disease)
11/2011
1Asthma (Bronchial Asthma)
02/2011
1Myocardial Infarction
03/2010
1Psoriasis (Pustulosis Palmaris et Plantaris)
03/2010

Drug/Important Bio-Agent (IBA)

4Monoclonal AntibodiesIBA
01/2014 - 03/2010
3sifalimumabIBA
01/2014 - 03/2010
2Ceftriaxone (Ceftriaxon)FDA LinkGeneric
01/2020 - 01/2019
2Pharmaceutical PreparationsIBA
01/2014 - 03/2010
1LactamsIBA
01/2019
1Anti-Bacterial Agents (Antibiotics)IBA
01/2019
1Interferon Type IIBA
11/2011
1InterferonsIBA
11/2011
1enokizumabIBA
02/2011
1Interferon-alpha (Interferon Alfa)IBA
03/2010

Therapy/Procedure

1Aftercare (After-Treatment)
01/2019